JP2001502792A - 診断法「a」 - Google Patents
診断法「a」Info
- Publication number
- JP2001502792A JP2001502792A JP10512739A JP51273998A JP2001502792A JP 2001502792 A JP2001502792 A JP 2001502792A JP 10512739 A JP10512739 A JP 10512739A JP 51273998 A JP51273998 A JP 51273998A JP 2001502792 A JP2001502792 A JP 2001502792A
- Authority
- JP
- Japan
- Prior art keywords
- pha
- lysine
- protein
- myeloperoxidase
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 活性化食細胞および(または)炎症が関与するアテローム性動脈硬化およ び同様な疾病の診断法およびスクリーニング試験法において、体液または組織試 料中に、p−ヒドロキシフェニルアルデヒド−リシンが正常被験者における濃度 と比べて高濃度で存在することを測定することからなる上記方法。 2. 試料はヒトの炎症組織である、請求項1記載の方法。 3. 試料はヒトの血清または血漿部分である、請求項1記載の方法。 4. p−ヒドロキシフェニルアルデヒド−リシンの存在および濃度を、質量分 析および高分解能NMR分光法により測定する、請求項1記載の方法。 5. p−ヒドロキシフェニルアルデヒド−リシンの存在および濃度を、前記p −ヒドロキシアルデヒド−リシンに対する抗体を用いる免疫検定法により測定す る、請求項1記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/709,700 | 1996-09-09 | ||
US08/709,700 US5731208A (en) | 1996-09-09 | 1996-09-09 | Method of detecting conditions indicative of atherosclerosis |
PCT/US1997/015115 WO1998010295A1 (en) | 1996-09-09 | 1997-09-03 | Diagnostic method for atherosclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001502792A true JP2001502792A (ja) | 2001-02-27 |
JP3553612B2 JP3553612B2 (ja) | 2004-08-11 |
Family
ID=24850989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51273998A Expired - Fee Related JP3553612B2 (ja) | 1996-09-09 | 1997-09-03 | アテローム性動脈硬化および同等な疾病のスクリーニング試験法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5731208A (ja) |
EP (1) | EP0931265B1 (ja) |
JP (1) | JP3553612B2 (ja) |
AT (1) | ATE217089T1 (ja) |
AU (1) | AU4165297A (ja) |
CA (1) | CA2264754C (ja) |
DE (1) | DE69712352T2 (ja) |
DK (1) | DK0931265T3 (ja) |
ES (1) | ES2176778T3 (ja) |
PT (1) | PT931265E (ja) |
WO (1) | WO1998010295A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017508139A (ja) * | 2014-01-31 | 2017-03-23 | イクセラ,インコーポレイテッド | バイオマーカーとしての共有結合した代謝物質 |
US10278958B2 (en) | 2012-03-28 | 2019-05-07 | Ixcela, Inc. | IPA as a protective agent |
US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727102B1 (en) | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
US6133039A (en) * | 1998-02-09 | 2000-10-17 | Washinton University | In vivo method for determination of oxidative stress |
US6096556A (en) * | 1998-02-09 | 2000-08-01 | Washington University | Method for the determination of oxidative stress |
SE9802402D0 (sv) * | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
US6309888B1 (en) * | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
ATE343130T1 (de) * | 1999-12-29 | 2006-11-15 | Perkinelmer Life Sciences Inc | Testtablett, kit und verfahren zum screening von körperflüssigkeiten von neugeborenen durch tandem-massenspektrometrie |
DK1353666T3 (da) | 2001-01-02 | 2013-10-14 | Cleveland Clinic Foundation | Myeloperoxidase, en risikoindikator for cardiovasculær sygdom |
US7780950B2 (en) * | 2002-01-02 | 2010-08-24 | The Cleveland Clinic Foundation | Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents |
US6939716B2 (en) * | 2001-09-19 | 2005-09-06 | Washington University | Method for detecting conditions indicative of sepsis |
US7459286B1 (en) | 2003-10-22 | 2008-12-02 | The Cleveland Clinic Foundation | Assessing the risk of a major adverse cardiac event in patients with chest pain |
WO2005055810A2 (en) | 2003-12-05 | 2005-06-23 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
US7378396B2 (en) | 2004-08-11 | 2008-05-27 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
-
1996
- 1996-09-09 US US08/709,700 patent/US5731208A/en not_active Expired - Fee Related
-
1997
- 1997-09-03 DE DE69712352T patent/DE69712352T2/de not_active Expired - Fee Related
- 1997-09-03 PT PT97939604T patent/PT931265E/pt unknown
- 1997-09-03 AU AU41652/97A patent/AU4165297A/en not_active Abandoned
- 1997-09-03 WO PCT/US1997/015115 patent/WO1998010295A1/en active IP Right Grant
- 1997-09-03 AT AT97939604T patent/ATE217089T1/de not_active IP Right Cessation
- 1997-09-03 DK DK97939604T patent/DK0931265T3/da active
- 1997-09-03 ES ES97939604T patent/ES2176778T3/es not_active Expired - Lifetime
- 1997-09-03 CA CA002264754A patent/CA2264754C/en not_active Expired - Fee Related
- 1997-09-03 JP JP51273998A patent/JP3553612B2/ja not_active Expired - Fee Related
- 1997-09-03 EP EP97939604A patent/EP0931265B1/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10278958B2 (en) | 2012-03-28 | 2019-05-07 | Ixcela, Inc. | IPA as a protective agent |
JP2017508139A (ja) * | 2014-01-31 | 2017-03-23 | イクセラ,インコーポレイテッド | バイオマーカーとしての共有結合した代謝物質 |
US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
US11287419B2 (en) | 2019-01-25 | 2022-03-29 | Ixcela, Inc. | Detection and modification of gut microbial population |
US11287417B2 (en) | 2019-01-25 | 2022-03-29 | Ixcela, Inc. | Detection and modification of gut microbial population |
US11287418B2 (en) | 2019-01-25 | 2022-03-29 | Ixcela, Inc. | Detection and modification of gut microbial population |
US11287420B2 (en) | 2019-01-25 | 2022-03-29 | Ixcela, Inc. | Detection and modification of gut microbial population |
Also Published As
Publication number | Publication date |
---|---|
AU4165297A (en) | 1998-03-26 |
ES2176778T3 (es) | 2002-12-01 |
EP0931265A1 (en) | 1999-07-28 |
ATE217089T1 (de) | 2002-05-15 |
JP3553612B2 (ja) | 2004-08-11 |
DE69712352D1 (de) | 2002-06-06 |
DE69712352T2 (de) | 2002-11-14 |
DK0931265T3 (da) | 2002-07-29 |
EP0931265B1 (en) | 2002-05-02 |
WO1998010295A1 (en) | 1998-03-12 |
CA2264754A1 (en) | 1998-03-12 |
CA2264754C (en) | 2005-11-22 |
US5731208A (en) | 1998-03-24 |
PT931265E (pt) | 2002-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001502792A (ja) | 診断法「a」 | |
Schleicher et al. | Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging. | |
Himmelfarb et al. | Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients | |
Rossi et al. | Immunoreactive endogenous ouabain primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels | |
Hazen et al. | p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies ε-amino groups of protein lysine residues | |
McGuire et al. | Localization of L-arginine-glycine amidinotransferase protein in rat tissues by immunofluorescence microscopy. | |
US20170016924A1 (en) | Methods for assessing the risk for development of cardiovascular disease | |
Soulis et al. | A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes | |
CA2821908A1 (en) | Novel biomarker and uses thereof in diagnosis, treatment of autism | |
Böger et al. | Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of l-[guanidino-15N2]-arginine to 15N-labeled nitrate by gas chromatography–mass spectrometry | |
JP3553611B2 (ja) | アテローム性動脈硬化および同様な疾病のスクリーニング試験法 | |
Guerby et al. | Modification of endothelial nitric oxide synthase by 4-oxo-2 (E)-nonenal (ONE) in preeclamptic placentas | |
CA2274776C (en) | Method for analyzing annexin v in urine and use thereof | |
Yocum et al. | Novel lipid hydroperoxide‐derived hemoglobin histidine adducts as biomarkers of oxidative stress | |
Fauler et al. | Enhanced urinary excretion of leukotriene E4 by patients with multiple trauma with or without adult respiratory distress syndrome | |
Tomida et al. | Immunohistochemical and biochemical studies of substances with taurine-like immunoreactivity in the brain | |
WO1996004311A1 (en) | Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease | |
Inoue et al. | Determination of nitrotyrosine and related compounds in biological specimens by competitive enzyme immunoassay | |
Doroszko et al. | Elevated plasma ADMA contributes to development of endothelial dysfunction in children with acute lymphoblastic leukemia | |
US7449338B2 (en) | Tests for the rapid evaluation of ischemic states and kits | |
US20120156704A1 (en) | In vitro method for detecting gp91phox as a marker of oxidative stress | |
AU778423B2 (en) | Placental human neurokinin B precursor | |
KR100605308B1 (ko) | PrxⅡ 단백질의 혈관 내피세포 탐지용 마아커로서의 용도 | |
JP2001004627A (ja) | メイラード反応後期生成物に対する自己抗体の免疫学的検出法 | |
Clive et al. | Evidence that circulating 6keto prostaglandin E1 causes the platelet defect of Bartter's syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20031209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040303 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040420 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040430 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080514 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090514 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100514 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110514 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120514 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |